Skip to navigation Skip to content

Acromegaly Program in Pharmaceutical Benefits Scheme (PBS) 012-18051100

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised pasireotide and pegvisomant for patients with acromegaly.

Acromegaly and listing dates

Acromegaly is a condition caused by excessive growth hormone.

Listing dates:

  • pasireotide - 1 September 2016
  • pegvisomant - 1 September 2017

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)

Written Authority Required Drugs